This measure assesses the percentage of adolescents 13 years of age who had one dose of meningococcal vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates. This measure follows the Advisory Committee on Immunization Practices (ACIP) guidelines for immunizations.
Why It Matters?
These vaccines are available for adolescents to prevent them from acquiring serious diseases and help protect against disease in populations that lack immunity, such as infants, the elderly and individuals with chronic conditions.
In 2022, data from NIS-Teen showed that 89.9% of adolescents surveyed had received a Tdap vaccine, 88.6% had received a meningococcal vaccine and 62.6% had received full doses of the HPV vaccine.1
*Adapted with financial support from the Centers for Disease Control & Prevention (CDC).
Historical Results – National Averages
Performance results for this measure are currently unavailable.
References
- Pingali, C., D. Yankey, L.D. Elam-Evans et al. 2023. “Vaccination Coverage Among Adolescents Aged 13-17 Years—National Immunizations Survey-Teen, United States, 2022.” MMWR Morb Mortal Wkly Rep 72:912–19. http://dx.doi.org/10.15585/mmwr.mm7234a3
- Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
- Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
- Print
Print this page.
Print this page.